Investor Presentaiton
Full year 2022
Delivered a landmark year
Achieved double-digit turnover +10%, adj.
operating profit growth +17%, excluding
COVID-19 solutions
Step change in commercial execution with
growth across the portfolio:
Specialty Medicines +29% (+15% excl.
Xevudy)
Vaccines +11% (+17% excl. pandemic
adjuvant)
General Medicines +1%
COVID-19 solutions sales of £2.4bn
R&D investment and strategic business
development support future growth
Absolute values at actual exchange rates (AER); changes at CER and full year 2022, unless
stated otherwise.
1. Continuing results represents performance excluding discontinued operations
2. Excluding COVID-19 solutions
GSK
Turnover¹
+13% (+10%²)
Adj. operating profit¹
+14% (+17%²)
£29.3bn £8.2bn
Adj. EPS¹
+15%
139.7p
Full
year
2023 guidance²
Sales growth: 6-8%
Free cash flow¹
£3.3bn
Adj. operating profit growth: 10-12%
Adj. EPS growth: 12-15%
6View entire presentation